Drug Profile


Alternative Names: AC 7700; AVE-8062; AVE8062A; RPR258063

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ajinomoto
  • Developer Sanofi
  • Class Amides; Antineoplastics; Small molecules
  • Mechanism of Action Tubulin polymerisation inhibitors; Vascular disrupting agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Fallopian tube cancer; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Soft tissue sarcoma; Solid tumours

Most Recent Events

  • 01 Nov 2014 Sanofi completes a phase I trial in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease) in France, Italy, United Kingdom (NCT01193595)
  • 30 Nov 2013 Sanofi completes a phase I trial in Solid tumours in Japan (NCT01293630)
  • 28 Feb 2013 Sanofi completes a phase I trial in Solid tumours in Europe (NCT00719524)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top